OP95
Anti-BRCA2 (Ab-1) Mouse mAb (2B)
liquid, clone 2B, Calbiochem®
Synonyme(s) :
Anti-Breast Cancer Susceptibility Protein
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
NACRES:
NA.43
UNSPSC Code:
12352203
Clone:
2B, monoclonal
Species reactivity:
human
Application:
—
Citations:
129
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
2B, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Immunoblotting (2 µg/mL)
Immunoprecipitation (2 µg))
isotype
IgG2b
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... BRCA2(675)
General description
Anti-BRCA2 (Ab-1), mouse monoclonal, clone 2B, recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. It is validated for Western blotting and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
Recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogen
Human
a recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
Application
Immunoblotting (2 µg/ml)
Immunoprecipitation (2 µg)
Immunoprecipitation (2 µg)
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In PBS.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
Analysis Note
Positive Control
MCF7 cells
MCF7 cells
Other Notes
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
The CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
Legal Information
Sold under license of U.S. Patents 5,837,492 and 6,124,104.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
Essayez notre Outil de sélection de produits pour affiner vos choix.
Classe de stockage
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Nathalie van den Tempel et al.
Cancers, 11(1) (2019-01-18)
The DNA damage response (DDR) is a designation for a number of pathways that protects our DNA from various damaging agents. In normal cells, the DDR is extremely important for maintaining genome integrity, but in cancer cells these mechanisms counteract
Nathalie van den Tempel et al.
PloS one, 13(12), e0209101-e0209101 (2018-12-15)
Bladder cancer (urothelial carcinoma) is a common malignancy characterized by high recurrence rates and intense clinical follow-up, indicating the necessity for more effective therapies. Current treatment regimens include intra-vesical administration of mitomycin C (MMC) for non-muscle invasive disease and systemic
Reihaneh Zarrizi et al.
The Journal of clinical investigation, 130(8), 4069-4080 (2020-05-08)
Haploinsufficiency of factors governing genome stability underlies hereditary breast and ovarian cancer. One significant pathway that is disabled as a result is homologous recombination repair (HRR). With the aim of identifying new candidate genes, we examined early-onset breast cancer patients